ABVX ABVX
Company Profile ↓Company Overview
ABVX (ABVX) is a publicly traded company listed on with a market capitalization of $9.85B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +73.98% |
| 6 Months: | +10.65% |
| 3 Months: | +1.30% |
| 1 Month: | -11.80% |
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)49.74 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | 47.20M | 46.50M | 80.71M | 71.65M | 56.23M |
| Operating Income | -47.20M | -46.50M | -80.71M | -71.65M | -56.23M |
| EBITDA | -47.56M | -44.64M | -148.87M | -60.56M | -45.33M |
| Interest Expense | 4.54M | 3.52M | 4.21M | 15.27M | 2.54M |
| Pretax Income | -52.37M | -48.41M | -153.36M | -76.11M | -48.24M |
| Tax Provision | 0 | 0 | 0 | 5.85M | 228.00K |
| Net Income | -52.37M | -48.41M | -153.36M | -81.96M | -48.47M |
| Diluted EPS | -0.83 | -0.76 | -2.10 | - | -0.61 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | 45.52M | 50.76M | - | - | - |
| Gross Profit | -45.52M | -50.76M | - | - | - |
| Operating Expenses | - | 51.20M | 127.38M | 172.98M | 246.06M |
| Operating Income | - | -51.20M | -127.38M | -172.98M | -246.06M |
| EBITDA | - | -53.31M | -133.21M | -162.71M | -300.70M |
| Interest Expense | - | 6.94M | 13.83M | 12.43M | 28.48M |
| Pretax Income | - | -60.74M | -147.74M | -176.24M | -330.25M |
| Tax Provision | - | 0 | 0 | 0 | 5.85M |
| Net Income | - | -60.74M | -147.74M | -176.24M | -336.10M |
| Diluted EPS | - | -3.18 | -3.43 | -2.78 | -4.83 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 75.54M | 327.06M | 205.23M | 584.34M |
| Current Assets | - | 36.18M | 285.97M | 170.67M | 551.24M |
| Cash & Equivalents | - | 26.95M | 251.94M | 144.22M | 516.68M |
| Inventory | 4.00M | - | - | - | - |
| Receivables | 1.47M | - | - | - | - |
| Total Liabilities | - | 68.36M | 131.05M | 164.64M | 129.14M |
| Current Liabilities | - | 51.46M | 88.11M | 92.83M | 63.02M |
| Long Term Debt | 34.61M | 8.29M | 26.62M | 52.16M | - |
| Total Debt | - | 39.16M | 58.04M | 97.36M | 1.86M |
| Total Equity | - | 7.19M | 196.01M | 40.58M | 455.20M |
| Shares Outstanding | - | 22.30M | 62.93M | 63.35M | 78.54M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -53.94M | -97.13M | -154.07M | -161.13M |
| Investing Cash Flow | - | -12.03M | -8.10M | 15.76M | -8.19M |
| Financing Cash Flow | - | 32.21M | 335.29M | 28.21M | 547.31M |
| Capital Expenditure | - | -323.00K | -265.00K | -643.00K | -142.00K |
| Free Cash Flow | - | -54.26M | -97.39M | -154.72M | -161.27M |
| Net Change in Cash | - | -33.75M | 230.06M | -110.10M | 382.71M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | - | -844.9% | -75.4% | -434.3% | -73.8% |
| ROCE % | - | -212.6% | -53.3% | -153.9% | -47.2% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ABVX
Evexta Bio Announces Clinical Trial Collaboration and Supply Agreement with Roche to Evaluate Rupitasertib in Combination with a Selective Estrogen Receptor Degrader in Advanced / Metastatic Breast Cancer
PARIS, August 04, 2026--Evexta Bio S.A., a precision oncology company, founded by Truffle Capital (founder of Abivax and Carvolix), and focused on the discovery and development of targeted therapies, today announced a clinical collaboration…
AbbVie Q2 Earnings Call Highlights
AbbVie (NYSE:ABBV) reported second-quarter 2026 results that exceeded its expectations, supported by double-digit growth in its immunology and neuroscience businesses, and raised its full-year revenue outlook by $300 million. Chairman and C…
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod
Abivax Announces Positive Pre-NDA Interaction with the FDA for Obefazimod Company remains on track to submit its first New Drug Application for obefazimod for the treatment of moderately to severely active ulcerative colitis by the end of 2…
Inflammatory Bowel Disease Market to Experience Strong Uptake During the Forecast Period (2026-2036), Driven by Development of Next-generation Therapies Targeting IL-23, TL1A, and S1P Pathways | DelveInsight
Recently published Inflammatory Bowel Disease Market Insights report includes a comprehensive understanding of current treatment practices, inflammatory bowel disease emerging drugs, market share of individual therapies, and current and for…
PK MED Strengthens Its Strategic and Scientific Governance to Support the Development of Its Therapeutic Micro-implants
PARIS & LYON, France, July 29, 2026--PK MED, a French biotechnology company founded by Truffle Capital (founder of Abivax and Carvolix), developing therapeutic micro-implants to address major medical needs, today announces a significant str…
ABIVAX Société Anonyme (ENXTPA:ABVX) Adds Commercial Leaders, Is The Upside Already Priced In?
ABIVAX Société Anonyme (ENXTPA:ABVX) has drawn fresh attention after expanding its commercial leadership team by adding four senior executives across marketing, patient services, sales and commercial operations, and market access for its le…
ABVX — Frequently Asked Questions
What is the current share price of ABVX?
As of 2026-08-05 17:25 PDT, ABVX trades at $125.39 on NASDAQ/NYSE. Its 52-week range is $68.96 to $145.31.
What is the market capitalisation of ABVX?
ABVX has a market capitalisation of $9.85B on NASDAQ/NYSE.
What is the P/E ratio of ABVX?
ABVX trades at a trailing price-to-earnings (P/E) ratio of -25.96. Its price-to-book (P/B) ratio is 21.63.
What is the return on equity (ROE) of ABVX?
ABVX has a return on equity (ROE) of -73.84%. Its return on capital employed (ROCE) is -47.20%.
Is ABVX a good stock to buy?
This page provides a data-driven analysis of ABVX, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.